Table 2.
Demographic, clinical and laboratory features of GBS not COVID-19 related.
| Patients (sex, age) | Antecedent event | Time between GBS onset and neurological evaluation (days) | protein (g/l) on CSF | GBS type | MRC score (T0-T1) | GBS-DS (T0-T1) | FU (days) |
|---|---|---|---|---|---|---|---|
| 1 (m,38) | None | 30 | 1.3 | MFS | 60–60 | 3–3 | 15 |
| 2 (m,51) | CMV related pneumonia and sepsis | 20 | 1 | AMAN | 32–42 | 4–4 | 15 |
| 3 (f,51) | None | 10 | 1.6 | AIDP | 40–48 | 4–2 | 45 |
| 4 (m,88) | Diarrhea | 30 | 0.9 | AMAN | 12–24 | 4–4 | 21 |
| 5 (f,72) | Pneumonia | 30 | NP | AIDP | 48–58 | 3–2 | 20 |
| 6 (m,50) | Flu syndrome | 5 | 1.42 | bilateral facial nerve palsies with paraesthesia | 60–60 | 1–1 | 30 |
| 7 (f,81) | None | 21 | 0.6 | Bickerstaff encephalitis | 48–48 | 4–4 | < 5 days |
| 8 (m,53) | Flu syndrome | 50 | 1 | AIDP | 46–46 | 3–3 | < 5 days |
| 9 (m, 82) | Flu syndrome | 60 | 0.3 | AIDP | 36–36 | 3–3 | < 5 days |
LEGEND: GBS, Guillain Barré syndrome; COVID-19 Coronavirus disease 19; CSF: cerebrospinal fluid; NP: not performed; MFS: Miller Fisher Syndrome; AIDP: acute inflammatory demyelinating polyradiculoneuropathy; MFS: Miller Fisher Syndrome; AMAN: acute motor axonal neuropathy; MRC; Medical Research Council; GBS-DS: GBS disability score; FU: follow up.